Inhibitory effect of reserpine on dopamine transporter function

Eur J Pharmacol. 2002 Dec 5;456(1-3):39-43. doi: 10.1016/s0014-2999(02)02647-x.

Abstract

Previous studies indicate that reserpine may disrupt dopamine transporter activity. Results presented herein reveal that it also inhibits potently synaptosomal [3H]dopamine uptake. In addition, reserpine administration to rats decreased the V(max) of synaptosomal dopamine transport, as assessed ex vivo 12 h after treatment. This decrease appeared, at least in part, dissociated from concurrent inhibition of the vesicular monoamine transporter-2 (VMAT-2). In separate experiments, synaptosomal dopamine uptake did not differ between wild-type and heterozygous VMAT-2 knockout mice, and reserpine treatment did not inhibit [3H]dopamine uptake into cells heterogously expressing the human dopamine transporter. Taken together, these data suggest that reserpine may transiently alter dopamine transporter function in a noncompetitive, indirect manner.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Biological Transport / drug effects
  • Dopamine / pharmacokinetics
  • Dopamine Plasma Membrane Transport Proteins
  • Humans
  • Male
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / physiology
  • Membrane Transport Proteins / physiology*
  • Mice
  • Mice, Knockout
  • Nerve Tissue Proteins*
  • Neuropeptides*
  • Rats
  • Rats, Sprague-Dawley
  • Reserpine / pharmacology*
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism
  • Time Factors
  • Tritium
  • Tumor Cells, Cultured
  • Vesicular Biogenic Amine Transport Proteins
  • Vesicular Monoamine Transport Proteins

Substances

  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Neuropeptides
  • Vesicular Biogenic Amine Transport Proteins
  • Vesicular Monoamine Transport Proteins
  • Tritium
  • Reserpine
  • Dopamine